ATE443768T1 - Impfstoff gegen staphylokokken-vergiftung - Google Patents

Impfstoff gegen staphylokokken-vergiftung

Info

Publication number
ATE443768T1
ATE443768T1 AT99943610T AT99943610T ATE443768T1 AT E443768 T1 ATE443768 T1 AT E443768T1 AT 99943610 T AT99943610 T AT 99943610T AT 99943610 T AT99943610 T AT 99943610T AT E443768 T1 ATE443768 T1 AT E443768T1
Authority
AT
Austria
Prior art keywords
staphylococco
poisoning
vaccine against
aureus
intoxication
Prior art date
Application number
AT99943610T
Other languages
English (en)
Inventor
John Lee
Peter Pushko
Jonathan Smith
Robert Ulrich
Original Assignee
U S Medical Res Inst Of Infect
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by U S Medical Res Inst Of Infect filed Critical U S Medical Res Inst Of Infect
Application granted granted Critical
Publication of ATE443768T1 publication Critical patent/ATE443768T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
AT99943610T 1998-07-10 1999-07-09 Impfstoff gegen staphylokokken-vergiftung ATE443768T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9241698P 1998-07-10 1998-07-10
PCT/US1999/015569 WO2000002523A2 (en) 1998-07-10 1999-07-09 Vaccine against staphylococcus intoxication

Publications (1)

Publication Number Publication Date
ATE443768T1 true ATE443768T1 (de) 2009-10-15

Family

ID=22233100

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99943610T ATE443768T1 (de) 1998-07-10 1999-07-09 Impfstoff gegen staphylokokken-vergiftung
AT99941953T ATE418612T1 (de) 1998-07-10 1999-07-09 Anthrax-impfstoff

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT99941953T ATE418612T1 (de) 1998-07-10 1999-07-09 Anthrax-impfstoff

Country Status (7)

Country Link
US (2) US6632640B1 (de)
EP (2) EP1097212B1 (de)
AT (2) ATE443768T1 (de)
AU (2) AU758019B2 (de)
CA (2) CA2337966A1 (de)
DE (2) DE69941454D1 (de)
WO (2) WO2000002523A2 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW517061B (en) * 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
US7087235B2 (en) 1997-06-25 2006-08-08 The United States Of America As Represented By The Secretary Of The Army Fusion protein of streptococcal pyrogenic exotoxins
CA2337966A1 (en) * 1998-07-10 2000-01-20 U.S. Medical Research Institute Of Infectious Diseases Vaccine against staphylococcus intoxication
AU762813B2 (en) * 1998-08-13 2003-07-03 Walter Reed Army Institute Of Research Bacterial superantigen vaccines
CA2366900A1 (en) 1999-04-16 2000-10-26 Stephen J. Wisniewski Drug delivery device comprising a dual chamber reservoir
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
GB0016702D0 (en) * 2000-07-08 2000-08-23 Secr Defence Brit Expression system
SE0102327D0 (sv) 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
GB0118009D0 (en) * 2001-07-24 2001-09-19 Regma Biotechnologies Ltd Novel preparation
ES2330202T5 (es) * 2001-09-06 2014-01-20 Alphavax, Inc. Sistemas vectores basados en replicones de alfavirus
IL162381A0 (en) * 2001-12-05 2005-11-20 Rakesh Bhatnagar A recombinant dna construct and a process for the preparation of a non-toxic anthrax vaccine
WO2003087378A1 (en) * 2002-04-11 2003-10-23 Powderject Research Limited Nucleic acid immunization
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
WO2004024067A2 (en) * 2002-09-10 2004-03-25 Vical Incorporated Codon-optimized polynucleotide-based vaccines against bacillus anthracis infection
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US20040208848A1 (en) * 2002-12-13 2004-10-21 Smith Jonathan F. Multi-antigenic alphavirus replicon particles and methods
US7442381B2 (en) * 2003-03-20 2008-10-28 Alphavax, Inc. Alphavirus replicons and helper constructs
WO2005034841A2 (en) * 2003-05-14 2005-04-21 Merck & Co., Inc. Anthrax vaccine
DE602004021260D1 (de) * 2003-07-11 2009-07-09 Alphavax Inc Cytomegalovirusimpfstoffe, die auf dem alphavirus basieren
EP1670505B1 (de) 2003-09-18 2012-11-14 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Dna-promotor und anthrax-vakzine
US8409590B2 (en) 2004-02-11 2013-04-02 Ligocyte Pharmaceuticals, Inc. Anthrax antigens and methods of use
NZ553776A (en) 2004-09-22 2010-05-28 Glaxosmithkline Biolog Sa Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide.
AU2006236910B2 (en) * 2005-04-11 2012-06-07 Purdue Research Foundation Vaccine against pandemic strains of influenza viruses
PT1931346E (pt) 2005-09-09 2012-08-14 Angelini Labopharm Llc Composição de trazodona para administração uma vez por dia
WO2007048219A2 (en) 2005-09-09 2007-05-03 Labopharm Inc. Sustained drug release composition
EP2476433A1 (de) 2006-03-30 2012-07-18 GlaxoSmithKline Biologicals S.A. Immunogene Zusammensetzung
US20070248960A1 (en) * 2006-04-19 2007-10-25 Rees Dianne M Arrays containing cleavable RNAi molecules
US8460913B2 (en) 2007-06-21 2013-06-11 Alpha Vax, Inc. Promoterless cassettes for expression of alpha virus structural proteins
JP5658564B2 (ja) 2007-08-31 2015-01-28 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌肺疾患および状態に対する免疫に関連した方法および組成物
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
WO2009063507A1 (en) * 2007-11-12 2009-05-22 Rakesh Bhatnagar Dna vaccine against anthrax
WO2010014304A1 (en) 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
EP2341929B1 (de) 2008-10-06 2017-01-25 University Of Chicago Zusammensetzungen und verfahren im zusammenhang mit bakteriellen emp proteinen
HUE026855T2 (en) 2009-04-03 2016-07-28 Univ Chicago Compositions and methods related to protein a (spa) variants
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP2555794A4 (de) 2010-04-05 2014-01-15 Univ Chicago Zusammensetzungen und verfahren im zusammenhang mit protein-a-(spa)-antikörpern als immunreaktionsverstärker
CA2803298C (en) 2010-07-02 2020-07-14 The University Of Chicago Compositions and methods related to protein a (spa) variants
EP2614074A1 (de) 2010-09-09 2013-07-17 The University of Chicago Verfahren und zusammensetzungen mit schützenden staphylokokken-antigenen
AU2012266880A1 (en) * 2011-03-16 2013-10-03 Regents Of The University Of Minnesota Compositions and methods for inducing immune responses against bacteria in the genus staphylococcus
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
BR112014003315A2 (pt) 2011-08-15 2017-03-01 Univ Chicago composições e métodos relacionados a anticorpos para a proteína a estafilocócica
JP6670106B2 (ja) 2012-04-26 2020-03-18 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌コアグラーゼ抗原およびその使用方法
CN104703622B (zh) 2012-04-26 2017-05-24 芝加哥大学 与金黄色葡萄球菌疾病期间抵消凝固酶活性的抗体相关的组合物和方法
EP3010535B1 (de) * 2013-06-19 2019-08-14 Integrated Biotherapeutics, Inc. Aus phenollöslichem modulin gewonnene toxoidpeptide, delta-toxin, superantigene und fusionen davon
KR20250071286A (ko) 2016-01-10 2025-05-21 네오티엑스 테라퓨틱스 엘티디. 면역강화제에 의해 증진되는 초항원 매개된 암 면역요법
US11505722B2 (en) * 2017-06-30 2022-11-22 The Boeing Company Nonaqueous sol-gel for adhesion enhancement of water-sensitive materials
JP7303791B2 (ja) 2017-07-27 2023-07-05 アブヴァク インコーポレイテッド スーパー抗原トキソイドに由来する融合ペプチドを含む免疫原性組成物
US12514914B2 (en) 2019-05-14 2026-01-06 The University Of Chicago Methods and compositions comprising Staphylococcus protein a (SpA) variants
CA3139899A1 (en) 2019-05-15 2020-11-19 Neotx Therapeutics Ltd. Cancer treatment
CN114929750B (zh) 2019-09-13 2024-11-22 芝加哥大学 用于治疗葡萄球菌感染的方法和组合物
JP2022550884A (ja) 2019-10-02 2022-12-05 ヤンセン ファッシンズ アンド プリベンション ベーフェー スタフィロコッカス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ）ペプチドおよび使用方法
CN115484978A (zh) 2020-03-05 2022-12-16 尼奥克斯医疗有限公司 使用免疫细胞治疗癌症的方法和组合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08500328A (ja) * 1992-01-28 1996-01-16 ナショナル ジューイッシュ センター フォア イミュノロジィ アンド レスパラトリィ メディスン 突然変異したスーパー抗原の保護作用
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
DK0814154T3 (da) 1993-09-15 2009-08-31 Novartis Vaccines & Diagnostic Rekombinante alfavirusvektorer
US5641655A (en) * 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
US5935568A (en) * 1995-05-18 1999-08-10 National Jewish Medical & Research Center Gene therapy for effector cell regulation
US5705151A (en) * 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
GB9604045D0 (en) * 1996-02-26 1996-04-24 Smithkline Beecham Plc Novel compounds
GB9618107D0 (en) * 1996-08-30 1996-10-09 Secr Defence Vaccine production
US6075119A (en) * 1997-04-07 2000-06-13 The Rockefeller University Peptides useful for reducing symptoms of toxic shock syndrome
US6261570B1 (en) * 1997-05-20 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants
US6713284B2 (en) * 1997-06-25 2004-03-30 The United States Of America As Represented By The Secretary Of The Army Bacterial superantigen vaccines
JP4422330B2 (ja) * 1998-02-15 2010-02-24 財団法人化学及血清療法研究所 新規な免疫異常性疾患予防・治療用剤
WO2000000616A2 (en) * 1998-06-29 2000-01-06 U.S. Medical Research Institute Of Infectious Diseases Marburg virus vaccines
CA2337966A1 (en) * 1998-07-10 2000-01-20 U.S. Medical Research Institute Of Infectious Diseases Vaccine against staphylococcus intoxication
AU762813B2 (en) * 1998-08-13 2003-07-03 Walter Reed Army Institute Of Research Bacterial superantigen vaccines
CA2354374A1 (en) * 1998-12-07 2000-06-15 U.S. Medical Research Institute Of Infectious Diseases Live attenuated venezuelan equine encephalitis vaccine

Also Published As

Publication number Publication date
AU5542699A (en) 2000-02-01
CA2337966A1 (en) 2000-01-20
US7374931B2 (en) 2008-05-20
ATE418612T1 (de) 2009-01-15
WO2000002522A3 (en) 2000-10-12
CA2339355A1 (en) 2000-01-20
AU758019B2 (en) 2003-03-13
EP1097212A2 (de) 2001-05-09
DE69940157D1 (en) 2009-02-05
WO2000002523A2 (en) 2000-01-20
US20040009183A1 (en) 2004-01-15
US6632640B1 (en) 2003-10-14
EP1097213A2 (de) 2001-05-09
WO2000002523A9 (en) 2000-07-27
WO2000002522A2 (en) 2000-01-20
WO2000002522A9 (en) 2001-04-05
AU761021B2 (en) 2003-05-29
WO2000002523A3 (en) 2000-11-23
EP1097213B1 (de) 2009-09-23
EP1097212B1 (de) 2008-12-24
AU5667399A (en) 2000-02-01
DE69941454D1 (de) 2009-11-05

Similar Documents

Publication Publication Date Title
ATE443768T1 (de) Impfstoff gegen staphylokokken-vergiftung
TR200806259T2 (tr) Tüberkülozun teşhisi ve immünoterapi yolu ile önlenmesine mahsus yöntemler ve bileşikler
CY1109531T1 (el) Πρωτεϊνες συντηξης του μυκοβακτηριδιου της φυματιωσης
WO2003070187A3 (en) Fusion proteins of mycobacterium tuberculosis
EA200100565A1 (ru) Новые стрептококковые антигены
DE602004020189D1 (de) Adjuvante influenza-vakzine
DE60130200D1 (de) 3-cyanochinoline, 3-cyano-1,6-naphthyridine und 3-cyano-1,7-naphthyridine als protein-kinaseinhibitoren
DE602004024542D1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
ATE382693T1 (de) Impfstoffe gegen neurotoxine von clostridium botulinum
BR0010418B1 (pt) microorganismo de salmonella, composiÇço de vacina e uso do referido microorganismo.
CY1106234T1 (el) Συνθεσεις για τη θepαπεια μολυνσεων staphylococcus aureus
ATE290548T1 (de) Expressionsblockierung von virulenten faktoren in s. aureus
WO2002034773A3 (en) Streptococcal genes
DK1625393T3 (da) Vacciner, som medfører beskyttelse mod infektion af Streptococcus pneumonia
TW200619228A (en) Immunogenic compositions of staphylococcus epidermidis polypeptide antigens
DE60239753D1 (de) Impfstoff gegen infektiöses lachsanämievirus
WO2003044047A3 (en) Virulence proteins of the genus yersinia and uses thereof
WO2002011549A3 (en) Treatment of mycobacterial infection
WO2004073603A3 (en) Dna vaccine that expresses mutant adp-ribosyltransferase toxins which display reduced, or are devoid of, adp-ribosyltransferase activity
ITMI20031872A1 (it) Copolimeri di poliesteri e polivinilpirrolidone.
RU97113193A (ru) Штамм бактерий bacillus anthracis 81/1, используемый в качестве тест-заражающей культуры
UA25233A (uk) Спосіб профілактики сибірки у твариh
AR010517A1 (es) Compuestos y metodos para la inmunoterapia y diagnostico de tuberculosis
CY1108864T1 (el) Ενωσεις για ανοσοθεραπεια και διαγνωση φυματιωσης και μεθοδοι χρησεις τους
AUPR001300A0 (en) Caged animal environment enrichment device

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties